

## CASE REPORT

# ESOPHAGEAL FOREIGN BODY IMPACTION AS A PRESENTATION OF UNDERLYING EOSINOPHILIC ESOPHAGITIS

Ruxandra OPRITA<sup>1,2✉</sup>, Madalina ILIE<sup>1,2</sup>, Vasile SANDRU<sup>1</sup>

<sup>1</sup> Clinical Emergency Hospital of Bucharest, Romania

<sup>2</sup> „Carol Davila“ University of Medicine and Pharmacy, Bucharest, Romania

Received 28 Dec 2018, Accepted 15 Febr 2019

<https://doi.org/10.31688/ABMU.2019.54.1.27>

### ABSTRACT

**Introduction.** Eosinophilic esophagitis (EoE) is a rare pathology characterized by chronic inflammation with mucosal eosinophilic infiltrate of the esophagus. The clinical symptoms vary according to the age group, from recurrent abdominal and thoracic pain, vomiting, dysphagia, food impaction and gastroesophageal reflux symptoms refractory to treatment with proton pump inhibitors. In the recent years, different studies suggest that EoE is now the leading cause of food impaction in the adult population.

**Case presentation.** A 30-year-old female, without a pathological personal history, was admitted with symptoms of esophageal food impaction. Upper endoscopy revealed esophageal rings and the bolus impacted in the lower esophagus. Biopsy samples were obtained from several different locations, including areas away from the site of food impaction. Histopathologic examination revealed esophageal mucosal eosinophilic infiltrate >15 eosinophils per high-power field. Proton pump inhibitor (PPI) therapy, twice-daily dosing for 8 weeks was administered, as the first line treatment.

**Conclusions.** Consensus guidelines for the diagnosis of EoE require symptoms of esophageal dysfunction,

### RÉSUMÉ

**Impaction alimentaire oesophagienne se présentant comme une oesophagite éosinophile sous-jacente**

**Introduction.** L'oesophagite éosinophilique (EoE) est une pathologie rare caractérisée par une inflammation chronique avec infiltration éosinophilique des muqueuses de l'oesophage. Les symptômes cliniques varient selon les groupes d'âge: douleur abdominale et thoracique récurrente, vomissements, dysphagie, impaction alimentaire et reflux gastro-oesophagien réfractaire au traitement par inhibiteurs de la pompe à protons. Au cours des dernières années, différentes études suggèrent que l'EoE est désormais la principale cause d'impaction alimentaire chez la population adulte.

**Présentation du cas.** Une femme âgée de 30 ans, sans antécédents personnels pathologiques, a été admise avec des symptômes d'impaction alimentaire oesophagienne. L'endoscopie supérieure a révélé des anneaux oesophagiens et le bolus touché dans le bas de l'oesophage. Des échantillons de biopsie ont été obtenus à plusieurs endroits différents, y compris dans des zones éloignées du site de l'impaction alimentaire. L'examen histopathologique a révélé un infiltrat

✉ Address for correspondence:

Ruxandra OPRITA  
Clinical Emergency Hospital of Bucharest, Gastroenterology Clinic,  
Bucharest, Romania  
Address: Calea Floreasca, no. 8, Bucharest, Romania  
Email: ruxandraa@netscape.net; Phone 0744202437

15 or more eosinophils per high-power field on microscopic examination of esophageal biopsy after 8 weeks on a high-dose proton pump inhibitor (PPI), and the absence of alternative causes of eosinophilia.

**Keywords:** eosinophilic esophagitis, endoscopy, food impaction, dysphagia.

## INTRODUCTION

Eosinophilic esophagitis (EoE) is an inflammatory disease characterized by eosinophilic infiltration of the esophageal mucosa<sup>1,2</sup>. The first case of eosinophilic inflammation was described by Dobbins in 1977<sup>3</sup>; however, until 1993, EoE was not defined as a pathology clinically different from the rest of the eosinophilic diseases of the gastrointestinal tract<sup>4</sup>. Despite the existence of few epidemiological data on the prevalence and incidence of EoE, the number of diagnosed cases has increased in recent years, probably due to the improvement in the knowledge of the disease<sup>5</sup>. The average age of development in children is between 7 and 10 years, and in adults between 30 and 40 years.<sup>6</sup> The pathophysiology is not entirely clear; however, there is an extensive knowledge that supports EoE as an immune-allergic alteration, possibly caused by food allergens.<sup>7</sup> Esophageal foreign body is more of a frequent pediatric presentation due to an underlying (EoE). In the past years eosinophilic esophagitis is increasingly being recognized as a background in a number of diseases and the interpretation of this pathology mostly depends on the clinical context in which it was obtained. The symptoms vary according to the age group, from recurrent abdominal and thoracic pain, vomiting, dysphagia, food impaction and heartburn, to developmental delay in children and gastroesophageal reflux symptoms refractory to treatment with proton pump inhibitors<sup>8,9</sup>. In the recent years, different studies suggest that EoE is now the leading cause of food impaction in adult population<sup>10,11</sup>. We present the clinical case of an adult patient with symptoms of esophageal bolus impaction, with acute dysphagia and mild chest pain, in whom flexible upper endoscopy revealed esophageal


éosinophilique de la muqueuse œsophagienne > 15 éosinophiles par champ de forte puissance. Un traitement par inhibiteurs de la pompe à protons (IPP), administré deux fois par jour pendant 8 semaines, a été administré à première intention.

**Conclusions.** Les directives consensuelles exigent des symptômes de dysfonctionnement œsophagien, 15 éosinophiles ou plus par champ de haute puissance lors de l'examen microscopique de la biopsie œsophagienne après 8 semaines d'inhibiteur de la pompe à protons (IPP) à haute dose, et l'absence de causes alternatives d'éosinophilie.


**Mots-clés:** œsophagite à éosinophiles, endoscopie, impaction alimentaire, dysphagie.

## CASE PRESENTATION

A 30 yo female, without pathological personal history, was admitted with symptoms of esophageal bolus impaction: acute dysphagia, mild chest pain, foreign-body sensation. During history, the patient revealed a similar episode approximately 5 years ago. Upper digestive endoscopy revealed bolus impaction (meat with fish bones) in the lower esophagus. During endoscopy, esophageal rings were observed (Fig. 1), along with the impacted bolus, which was advanced gently into the stomach with the flexible endoscope, without immediate complications. After the procedure, the patient no longer had a foreign-body sensation in the esophagus, but a strong epigastric pain. The emergency chest radiography detected sub-diaphragmatic free gas on the right side and the patient was admitted to the hospital with the suspicion of esophageal perforation. Blood tests revealed inflammatory syndrome, with a C-reactive protein of 216 U/mL and marked leukocytosis with neutrophilia. The patient developed fever in the next 24 hours. Chest computed tomography was performed, which revealed right pneumoperitoneum and subcutaneous emphysema. Conservative treatment was adopted, with a favorable evolution. During the hospitalisation, after the spontaneous resolution of the pneumoperitoneum and subcutaneous emphysema, biopsy samples (Fig. 2) were obtained from several different locations, including areas away from the site of food impaction. Histopathological findings revealed esophageal mucosal eosinophilic infiltrate >15 eosinophils per high-power field. Proton pump inhibitor (PPI) therapy, twice-daily dosing for 8 weeks, was administered along with dietary restrictions and skin sensitivity tests for food and pneumo-allergens. Upper endoscopy, along with multiple biopsy samples, will be repeated after the 8 weeks trial. If neither



**Fig. 1.** Esophageal rings revealed at upper endoscopy



**Fig. 2.** Multiple biopsy samples taken along the length of the esophagus

symptoms nor histology improve, the diagnosis of EoE is confirmed and the PPI treatment discontinued and replaced by topical corticosteroids.

## DISCUSSION

EoE is a rare pathology, characterized by inflammation with an eosinophilic infiltrate of the esophagus, without gastroesophageal reflux. The pathophysiology is not yet fully established. There are several theories that relate endogenous and environmental factors<sup>12</sup>. Based on the results of several studies, two types of mechanisms were observed: one dependent on IgE, or extrinsic, in relation to the atopic predisposition, the high serum IgE values and the high percentage of patients positive for intradermal sensitivity tests; and another, independent of IgE, or intrinsic, in association with a high percentage of patients with positive epicutaneous tests not dependent on IgE, in which it is believed that T lymphocytes play a fundamental role<sup>13</sup>. Skin sensitivity tests for food and for pneumo-allergens help identify allergens and the atopic status of patients with EoE<sup>14</sup>. The immune-allergic mechanism can be triggered in the esophagus, in the bronchi or even in the skin. The most frequent clinical manifestations vary according to the age group. The most common endoscopic findings are: linear esophageal grooves, esophageal rings, whitish granulation and esophageal stenosis, in some cases the mucosa appears pale, congested, or has decreased vascularity<sup>15</sup>. The whitish plaques are associated with the finding of eosinophilic micro abscesses and areas of high density of eosinophilic infiltrate or can mimic candida<sup>16</sup>. The diagnosis of EoE should be suspected based on clinical characteristics and endoscopic findings. However, definitive confirmation must be anatomopathological; the presence of more than 15 eosinophils per high-power field is the definitive diagnostic criteria<sup>17</sup>. The differential diagnosis should be

done with gastroesophageal reflux disease, because it also increases the number of esophageal eosinophils; however, the increase is never greater than 10 eosinophils per high-power field<sup>18</sup>. This increase occurs mainly in the distal esophageal. Currently, there is no definitive treatment for EoE. Some studies have used topical corticosteroids, such as fluticasone propionate at a dose of 220 mcg (2-4 puffs swallowed every 12 hours) for 4-6 weeks<sup>19</sup>. Systemic corticosteroids, such as methylprednisolone, in doses of 0.5-1 mg/kg for 6 consecutive months, with a progressive descending regimen, are an alternative. Other medical therapies include the use of montelukast, with which an improvement of the symptoms is observed but not of the histology, in addition to an early relapse after its interruption. Patients with stenotic lesions will require endoscopic esophageal dilatations<sup>20</sup>. Other studies have been conducted with mepolizumab, a biological anti-IL-5 agent, which is administered in a 3-monthly infusions of 10 mg/ kg<sup>21</sup>.

## CONCLUSIONS

EoE is an increasingly important cause of dysphagia and food impaction in adults. There are multiple characteristic endoscopic findings in EoE, but these endoscopic findings are also not specific for diagnosis of EoE. It is recommended that esophageal biopsies should be obtained in all patients suspected of having EoE, including all patients who undergo upper endoscopic evaluation for dysphagia or food impaction, regardless of the endoscopic appearance or findings. Consensus guidelines require symptoms of esophageal dysfunction, 15 or more eosinophils per high-power field on microscopic examination of esophageal biopsy after 8 weeks on a high-dose proton pump inhibitor (PPI), and the absence of alternative causes of eosinophilia<sup>22,23</sup>.

**Compliance with Ethics Requirements:**

„The authors declare no conflict of interest regarding this article“

„The authors declare that all the procedures and experiments of this study respect the ethical standards in the Helsinki Declaration of 1975, as revised in 2008(5), as well as the national law. Informed consent was obtained from the patient included in the study“

„No funding for this study“

**REFERENCES**

1. Ferguson DD, Foxx-Orenstein AE. Eosinophilic esophagitis: an update. *Dis Esophagus*. 2007;20(1):2-8.
2. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. *J Allergy Clin Immunol*. 2011;128(1):3-20.
3. Dobbins JW, Sheahan DG, Behar J. Eosinophilic gastroenteritis with esophageal involvement. *Gastroenterology*. 1977;72(6):1312-6.
4. Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 years of eosinophilic esophagitis: clinical features and prognosis. *J Pediatr Gastroenterol Nutr*. 2009;48(1):30-6.
5. Mackenzie SH, Go M, Chadwick B, et al. Eosinophilic esophagitis in patients presenting with dysphagia - a prospective analysis. *Aliment Pharmacol Ther*. 2008;28(9):1140-9.
6. Collins MH. Histopathologic features of eosinophilic esophagitis. *Gastrointest Endosc Clin N Am*. 2008;18(1):59-71.
7. Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus - peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. *Am J Gastroenterol*. 2006;101(7):1666-70.
8. Peery AF, Shaheen NJ, Dellon ES. Practice patterns for the evaluation and treatment of eosinophilic oesophagitis. *Aliment Pharmacol Ther*. 2010;32(11-12):1373-82.
9. Attwood SE, Smyrk TC, Demeester TR, et al. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. *Dig Dis Sci*. 1993;38(1):109-16.
10. Ferré-Ybarz L, Nevot Falcó S, Plaza-Martin AM. Eosinophilic esophagitis: clinical manifestations and treatment options. The role of the allergologist. *Allergol et Immunopathol*. 2008;36:358-65.
11. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. *N Engl J Med*. 2004;351(9):940-1.
12. Orenstein SR, Shalaby TM, Finch R, et al. The spectrum of pediatric eosinophilic esophagitis beyond infancy: a clinical series of 30 children. *Am J Gastroenterol*. 2000;95:1422-30.
13. Rothenberg ME. Biology and treatment of eosinophilic esophagitis. *Gastroenterology*. 2009;137(4):1238-49.
14. Putnam PE. Evaluation of the child who has eosinophilic esophagitis. *Immunol Allergy Clin North Am*. 2009;29:1-10.
15. González FG, Torres J, Molina UR, Harris PR. Esófagitis eosinofílica en niños: características clínicas y endoscópicas. *Rev Med Chile*. 2009;137:666-71.
16. Moy N, Heckman MG, Gonsalves N, et al. Inter-observer agreement on endoscopic esophageal findings in eosinophilic esophagitis. *Gastroenterology*. 2011;140:S-236.
17. Miller SM, Goldstein JL, Gerson LB. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD. *Am J Gastroenterol*. 2011;106(8):1439-45.
18. Foroutan M, Norouzi A, Molaei M, et al. Eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease. *Dig Dis Sci*. 2010;55(1):28-31.
19. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. *Gastroenterol*. 2007;133:1342-1363.
20. Assa'ad AH, Putnam PE, Collins MH, et al. Pediatric patients with eosinophilic esophagitis: an 8- year follow-up. *J Allergy Clin Immunol*. 2007;119(3):731-738.
21. Sha A, Hirano I. Treatment of eosinophilic esophagitis: drugs, diet, or dilatation? *Gastroenterol Rep*. 2007;9:181-8.
22. Molina-Infante J, van Rhijn BD. Interactions between gastro-oesophageal reflux disease and eosinophilic oesophagitis. *Best Pract Res Clin Gastroenterol*. 2015;29:749-758.
23. Orenstein SR, Shalaby TM, Di Lorenzo C, et al. The spectrum of pediatric eosinophilic esophagitis beyond infancy: a clinical series of 30 children. *Am J Gastroenterol*. 2000;95:1422-30.